[Federal Register Volume 85, Number 34 (Thursday, February 20, 2020)]
[Notices]
[Pages 9790-9791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03333]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Development of Clinical Outcome Assessments for 
Clinical Trials in Substance Use Disorders as FDA-qualified Drug 
Development Tools (U01 Clinical Trial Optional).
    Date: March 6, 2020.
    Time: 1:30 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center (NSC), 
Building 6001 Executive Boulevard, Room 4235, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, 6001 Executive 
Boulevard, Room 4235, MSC 9550, Bethesda, MD 20892-9550, 301-827-
5819, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Workshops on the Use of Adolescent Brain Cognitive 
Development (ABCD) Data (R25 Clinical Trial Not Allowed).
    Date: March 16, 2020.
    Time: 1:00 p.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center (NSC) 
Building, 6001 Executive Boulevard, Room 4229, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 
4245, Rockville, MD 20852, 301-435-1426, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Research Networks for the Study of Recovery Support 
Services for Persons Treated with Medications for Opioid Use 
Disorder (R24 Clinical Trial Optional).
    Date: March 17, 2020.
    Time: 12:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center (NSC) 
Building, 6001 Executive Boulevard, Room 4235, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, 6001 Executive 
Boulevard, Room

[[Page 9791]]

4235, MSC 9550, Bethesda, MD 20892-9550, 301-827-5819, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: February 13, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-03333 Filed 2-19-20; 8:45 am]
 BILLING CODE 4140-01-P